These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35253555)

  • 1. A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression.
    Tamman A; Anand A; Mathew SJ
    Expert Opin Drug Saf; 2022 Jun; 21(6):745-759. PubMed ID: 35253555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
    Mathew SJ; Wilkinson ST; Altinay M; Asghar-Ali A; Chang LC; Collins KA; Dale RM; Hu B; Krishnan K; Kellner CH; Malone DA; Murrough JW; Ostroff RB; Sanacora G; Shao M; Anand A
    Contemp Clin Trials; 2019 Feb; 77():19-26. PubMed ID: 30572160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commentary: Treatment-resistant Depression: Considerations Related to ECT and Ketamine.
    Garakani A
    J Psychiatr Pract; 2021 Nov; 27(6):496-497. PubMed ID: 34768276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
    Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
    Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.
    Terao I; Tsuge T; Endo K; Kodama W
    J Affect Disord; 2024 Feb; 346():49-56. PubMed ID: 37949235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy.
    Baldinger-Melich P; Spies M; Bozic I; Kasper S; Rujescu D; Frey R
    Wien Klin Wochenschr; 2024 Apr; ():. PubMed ID: 38662240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine for depression clinical issues.
    Iqbal SZ; Mathew SJ
    Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and adverse effects of ketamine versus electroconvulsive therapy for major depressive disorder: A systematic review and meta-analysis.
    de A Simoes Moreira D; Gauer LE; Teixeira G; Fonseca da Silva AC; Cavalcanti S; Quevedo J
    J Affect Disord; 2023 Jun; 330():227-238. PubMed ID: 36907464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression.
    Zhong X; He H; Zhang C; Wang Z; Jiang M; Li Q; Zhang M; Huang X
    J Affect Disord; 2016 Sep; 201():124-30. PubMed ID: 27208499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial.
    Altinay M; Karne H; Anand A
    Psychopharmacol Bull; 2019 Feb; 49(1):8-16. PubMed ID: 30858635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression.
    Degerlund Maldi K; Asellus P; Myléus A; Norström F
    BMC Psychiatry; 2021 Dec; 21(1):610. PubMed ID: 34876085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review.
    Veraart JKE; Smith-Apeldoorn SY; Spaans HP; Kamphuis J; Schoevers RA
    J Affect Disord; 2021 Feb; 281():82-89. PubMed ID: 33307338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IV esketamine for patients with a treatment-resistant depression].
    Stuiver S; Van Verseveld M; Koning MV; De Wit NCJ; Van Waarde JA
    Ned Tijdschr Geneeskd; 2023 Aug; 167():. PubMed ID: 37565823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
    Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
    [No Abstract]   [Full Text] [Related]  

  • 18. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
    Ekstrand J; Fattah C; Persson M; Cheng T; Nordanskog P; Åkeson J; Tingström A; Lindström MB; Nordenskjöld A; Movahed Rad P
    Int J Neuropsychopharmacol; 2022 May; 25(5):339-349. PubMed ID: 35020871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of the Efficacy and Adverse Effects of Ketamine and Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: A Systematic Review.
    Chaudhri SI; Amin A; Panjiyar BK; Al-Taie DS; AlEdani EM; Gurramkonda J; Hamid P
    Cureus; 2024 Mar; 16(3):e55596. PubMed ID: 38576655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.